UBS Group
OKUR

UBS Group’s OnKure Therapeutics OKUR Stock Holding History

UBS Group’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$454K Buy
99,604
+96,209
+2,834% +$413K ﹤0.01% 6297
2026
Q1 		$14.1K Buy
3,395
+2,187
+181% +$6.75K ﹤0.01% 8195
2025
Q4 		$3.5K Buy
1,208
+1,003
+489% +$3K ﹤0.01% 9006
2025
Q3 		$564 Buy
205
+24
+13% +$59 ﹤0.01% 9624
2025
Q2 		$433 Sell
181
-99
-35% -$260 ﹤0.01% 9827
2025
Q1 		$1.2K Sell
280
-1,933
-87% -$10.9K ﹤0.01% 9554
2024
Q4 		$19K Buy
2,213
+2,094
+1,760% +$31.7K ﹤0.01% 7911
2024
Q3 		$2.02K Sell
119
-1,000
-89% -$14.8K ﹤0.01% 8517
2024
Q2 		$16.9K Sell
1,119
-69
-6% -$1.17K ﹤0.01% 7412
2024
Q1 		$19.7K Sell
1,188
-457
-28% -$7.54K ﹤0.01% 6933
2023
Q4 		$26.3K Sell
1,645
-1,227
-43% -$76.5K ﹤0.01% 6927
2023
Q3 		$219K Sell
2,872
-3,484
-55% -$237K ﹤0.01% 5309
2023
Q2 		$417K Buy
6,356
+1,060
+20% +$85.4K ﹤0.01% 4977
2023
Q1 		$317K Sell
5,296
-459
-8% -$16.6K ﹤0.01% 5035
2022
Q4 		$134K Sell
5,755
-5
-0.1% -$133 ﹤0.01% 5819
2022
Q3 		$193K Buy
5,760
+305
+6% +$10K ﹤0.01% 5117
2022
Q2 		$145K Buy
5,455
+5,348
+4,998% +$124K ﹤0.01% 5149
2022
Q1 		$3K Sell
107
-159
-60% -$8.9K ﹤0.01% 9503
2021
Q4 		$23K Buy
+266
New +$19.5K ﹤0.01% 7689

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group's OKUR Position: Q2 2026 in Review

UBS Group increased its OnKure Therapeutics (OKUR) stake by 2,834% in Q2 2026, buying an estimated $413K and bringing the position to 99,604 shares worth $454K. The position accounts for ﹤0.01% of the portfolio, ranked #6297.

UBS Group first reported a position in OKUR in Q4 2021 and has held it in 19 quarters since. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • UBS Group held 99,604 shares of OnKure Therapeutics worth $454K as of Q2 2026.
  • UBS Group bought 96,209 OnKure Therapeutics shares in Q2 2026, an estimated $413K.
  • OnKure Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6297 holding.
  • UBS Group first reported a position in OnKure Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.